|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01011 NT PHARMA
Nominal 
0.440 +0.005 (+1.149%) | 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 37,960 | 415.341% | 7,366 | 207,092 | 226,699 | 221,731 |
| Cost of Sales | (32,700) | -- | -- | (81,806) | (81,240) | (86,827) |
| Gross Profit | 5,260 | -- | -- | 125,286 | 145,459 | 134,904 |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | (78) | -- | 10,980 | |
| Change in FV & Impairment on Others | (5,922) | -- | -- | -- | (14,011) | (68,706) | |
| Profit / (Loss) on Disposal | -- | -- | 12,272 | -- | -- | -- | |
| Other Non-operating Items | (7,009) | -- | -- | (11,318) | (5,807) | -- | |
| Share of Results of Asso. & JCEs | 10,244 | -72.343% | 37,039 | 9,003 | 34,490 | 8 | |
| Profit / (Loss) before Taxation | (53,480) | 60.269% | (33,369) | (54,296) | (148,752) | (200,289) | |
| Taxation | 123 | -- | (122) | (12,109) | (2,582) | 9,020 | |
| Profit / (Loss) from Discontinued Operations | -- | -- | (110,099) | -- | -- | (168,644) | |
| Non-controlling Interests | 0 | -- | 0 | 0 | 1,796 | 2,314 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (53,357) | -62.841% | (143,590) | (66,405) | (149,538) | (357,599) | |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 31,533 | 9.455% | 28,809 | 71,710 | 88,488 | 83,702 |
| Depreciation & Amortisation | 660 | -45.589% | 1,213 | 21,070 | 42,249 | 24,397 |
| Directors' Emoluments | -- | -- | 2,231 | 3,609 | 3,774 | 4,417 |
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | Disclaimer | -- | Disclaimer | Disclaimer | Disclaimer | Unqualified (Modified Report) |
Market Valuation Indicators
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | -20.200 | -66.445% | -60.200 | -34.900 | -79.100 | -189.500 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | 0.212 | 0.191 | (0.072) | 0.014 |
| NBV per share ($) | (1.511) | -- | (1.286) | (1.269) | (1.109792) | 0.08547 |
| Remarks: | Real time quote last updated: 05/06/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (¥) | RMB -53,357,000 |
| %Change | -62.841% |
| EPS / (LPS) | RMB -0.202 |
| NBV Per Share (¥) | RMB -1.511 |